So unbelievably frustrating.

The questions that need to be answered is, why did we get involved with these clowns in the first place? Who commits to $20 million and can't close on two deadlines?

NOTHING changed materialistically in regards to the science/data from when they announced financing to the deadlines, so why would Schneider back out?

Absolute disaster. 5 MILLION MARKET CAP? The local car dealer is worth as much as this company according to the market. Almost 9x for InMed!??!?!

Who wanted out?

I want progress. Ill be in until Murphy is in his grave.

Clicking my heels 3 times today for the close of financing and announcement of IND in October.

This is excruciatingly painful.

At some point theyve got to invest in getting their name out there. IMLFF's pumps are just a representation of the market in 2017. If you dont invest capital in promotion then you let the crooks have complete control to decimate the SP, which in turn decimates the company. And the crooks will NEVER LOSE.

Frustrating.

NEW ARTICLE:

https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10002943/nemus-bioscience-ceo-talks-waves-of-dominance-in-the-ca

I dont see anything relatively new or exciting here, nor does it really say if this interview is new with Murphy or just re-hashed from the previous Benzinga interview. Maybe the pot will start to stir.

Can always count it on the crooks to bring it down. Theyve been working extra hard the last couple of weeks!

Well the good thing about August ending is that we're 2/3 through 3Q and 48 days through the financing 90 day extension. Which means we're as close as we've ever been and the IND for NB1222 is hopefully 60 days away. Murphys "3Q or 4Q" timeline will defintiely now be 4Q but we can almost taste it!

I dont think anybody expects the $20 mill injection to get to approval stage, nor should it even be discussed. All it needs to do is get us to higher valuations for another moderate raise that brings us to Phase 3 trials.

The 502(b) filing for NB1222 is infinitely less costly than a normal NDA process, and they've directed much of their focus to this. Once they get past the first Phase 2 trials, the market cap will undoubtedly allow for a another large raise that doesnt dilute to heavy.

In a perfect world, share price gets to 5+ in 2018 then, raise another 100 million for 20,000,000 shares, giving us capital for other indications and completion of Phase 3 for CINV. At that point we'll have enough champagne to pass around from the share price increase : )

Wouldn't get beat up about it. Partnerships for early trials are less likely and less important because theyre smaller sample sizes and are testing for safety primarily, and they cost a fraction of the price.

Broad Phase 3 trials (and can be multiple phase 3 designed differently) are where you start to hit the 100-200+ million mark for completion, which is where a partnership would be critical.

Nauseating at the moment, yes, but this is biotech to the T.
-----------

Take a gander at the 5-year chart for Aurinia Pharma. Totally different market with Lupus but you have a dead "downtrend" for 3 years while conducting trials and then a 5-bagger in 2 months on succesful Phase 2. Now they are the crown jewel of clinical-stage biotech.

You saw the hype with $ZYNE. They blew through a $350 mill market cap on hype leading up to Phase 2 trial results. It'll come.

Its par for the course in biotech. This raise is neccessary and will propel shares to higher valuations. If Murphy & Co wanted less money for less dilution, they wouldve raised less. This isn't their first rodeo.

In theory, and Vinpat has touched base on this, the team believes there is incredible value behind the science and IP, and therefore its only a matter of time before the market catches fire.

Progressing through Phase 2 trials for both CINP & Glaucoma sucessfully with the 20 million (key word SUCCESSFULLY), would blow the share price over $5 even with 100mill fully diluted, and then they can do another moderate raise to finish trials, or partner (which Murphy has said they prefer do to, cough cough, Allergan + Doug Ingram)

Either way, downtrend is a product of bio company tendencies, not anything that Nemus is doing wrong.

Not bearish in the slighest. There is literally no volume so the daily ticks down are not important.

It will all come into fruition with the filing of the first IND. Blue skies after that, and we might see some sunshine with the close of the $20 million and the Fall pot stock craziness, and the looming legalization in California. Not to mention the daily articles of the the booming CBD industry and the public shift to recognizing its medicinal properties.

It will come fast and all at once if you can stomach the fact that, we are in fact the early birds.

Nothing yet. Pretty debillitating but it should come through.

Rather comical though to commit to $20 million and not be able to pony up the $$$ when the time comes. Not exactly a small amount of money to agree to.

They had a 90 day extension but one would hope that they dont need the full 90 days. After all Nemus needs the dough!

Looking forward to having a beer together when the market wakes up and we are out of hell. By then VBIO will be at a 4 billion market cap.

I'd say this news is pretty good. Any time they are presenting data for the superiority of their compounds is a good sign and means the lulls of time are being put to good use.

There's really only two catalysts in the near-term that you (we) are looking for, and thats the close of financing and the filing of the 502(B) for CINV. I think at this point Murphy is trying to be as close to accurate as possible with timelines, in which case that was "3Q or 4Q" for the IND. We're halfway through 3Q, so realistically October is where we should be antsy for the IND.

ZYNE unfortunately came up short in their Phase 2 trial for ZYN002...bad for medical community, hopefully get a boost here.

We've been chattering about how NEMUS science has been better for years from the get-go, so maybe $$$ will flow into here.

Going to pray every night that this $20 million closes so we can get out of this 10-month deathspiral hellhole.

Incredible that VBIO is valued 6x NEMUS. 6! How long are we gonna have this conversation month after month!??!?!?

They closed a round of $1 mil in financing which is laughable in biotech and they may be literally 18 months behind NEMUS in starting trials.

Delusional market.

Thank god the market doesnt care at all. For a second I thought this information was pertinent at all in biotech.

I think my local Rite-Aid could raise more interested investors.

News: http://news.sys-con.com/node/4131256

Solid. Love good data.

As discussed on this board before, Murphy is hellbent on broadening the portfolio for increase company and shareholder value. Multiple shots on deck is the name of the game!

Good read but the 505(b)(2) for NB1222 is understated in your analysis for how much value it brings to shareholders.

Formulation development is well underway for NB1222 and approval for the 505 (b) (2) will expedite the process immediately to Phase 2 trials (while conducting phase 1 in non-clinical studies). Also in some instances, Phase 3 trials are not neccessary since they rely on previous data, however I'd expect a small phase 3 trial to not get ahead of ourselves. See below info:
https://camargopharma.com/what-is-505b2/

This indication is also not something that needs 52 week or even 24 week analysis, so trials will be on the speedier side in the typical 505(b)(2) world.

The market cap should trade significantly higher if this NDA is accepted. I resist using the term rocket ship, but jumping from the completely unknown to Phase 2 trials could prove to do so.

All while there will be additional updates in the fall on the following:

- November 11-15 Neurosciene NB2222 Pain Data - http://www.nemusbioscience.com/investor-relations/investor-news/investor-news-details/2017/NEMUS-Bioscience-Announces-NB2222-Pain-and-Anti-Addiction-Data-Accepted-for-Presentation-at-Upcoming-Society-of-Neuroscience-Meeting/default.aspx

- NB1111 Glaucoma Progress
- NB3111 MRSA Progress

-

Holding 52,000 shares until 2020. WE AINT GOING ANYWHERE.

Just painful to see interest in cannabinoid companies everywhere but here. Head scratcher for a year now.

1) Need that financing close.
2) Need 502(b) application for CINV.
3) Need the speculators for the rest of the pipeline to start driving this!

Scratch that. month to month, and quarter to quarter.

even the patient get impatient!

Its as if there are 6 people in the entire world that have any interest in investing in this company. Literally mind-blowing this day-to-day stuff.

So bizarre the complete lack of volume in this but loads of interest in other cannabinoid biotechs.

Guess well just have to wait till FDA approval to shoot up 4,000% in 3 days. Love the markets!

Coke dealers, heroine dealers. Its all the same.

INSY trades at a market cap just shy of a billion dollars, and they are in an endless spiral of controversy and shady dealings.

This is a blip on the radar. Financing will come into place soon.

Really not concerning.

We're investing in Nemus, not Schneider Bros. The money could come from coke dealing for all we care.

A lot of work done to this point by the Univ. of Missip team, and Murphy and Co. over the last couple of years, while being transparent and forthcoming with the sole focus on good data and advancing research into trials, no smokescreens.

Seems like a witch hunt. Wouldn't be too worried. Murphy has been by the book with everything, this isnt anything different besides a small delay, in which Murphy promptly notified the community without trying to hide anything. Completely transparent.

Seems like a witch hunt. Wouldn't be too worried. Murphy has been by the book with everything, this isnt anything different besides a small delay, in which Murphy promptly notified the community without trying to hide anything. Completely transparent.

"The guaranty provides that, in case of default by the Purchaser, SB Securities Ltd., an affiliate of Schneider Brothers Ltd., shall pay $20 million, upon written demand by the Company, and without any opposition."

Guarantee is a nice word.

Nothing really changes.

The market cap is already at a absurdly low level. What are the crooks gonna take us to a 5 million market cap?

Got all that info. Just wondering when the dilution is expected to hit or if theres something in the the deal that delays it so as not to crush the SP, which would be ideal for (1) Massive correction north (2) Easier path to uplisting on higher exchange

Vinpat

Do you have a understanding of timeline when the convertible shares for Schneider will bake into the market cap?

Must say, It's nice to be sitting at this market cap for the time being while still floating in the "undiscovered" range, which would bode well for an absurd move north upon the NDA.

I'm almost positive CARA's drugs arent technically cannabinoid based drugs. There was some market confusion that was perpetuated through the internet (suprise, suprise), but their drugs work entirely differently through kappa opiod receptors.

This basically brings a variety of different factors into play when breaking down the efficacy. And it looks like nobody has the answers yet! ha!

Many factors come into that sell-off in the 2017 world of investing in these biotech companies. The actual data they released isn't a death sentence by any means, but the stock fluctuation will make it seem like that.

- Massive run-up due to almost-perfect market sentiment and a couple strong catalysts
- Hot sector of biotech with the opiod crisis, makes it ripe for over-exuberance on a drug that disrupts the opiod market
- Ease of access for the average investor these days to invest turns in to mass-panic at the very second the market sentiment changes, hence CARA.

NEMUS will benefit in the near future of this over-exuberance. 2nd Half 2017 and 2018 will be hot fire with biotech, cannabinoids, and more robinhood accounts getting created on the daily for small-time folk to jump in.

You're a saint. This information is invaluable.

Even if they start to take profits before-hand, we retail can as well, so everybody wins.

So very looking forward to more MRSA data, their pain-trial candidate, and the looming CINV trials.

Market cap for AXIM is closer to 900 million-1 Billion, if you're using the same comparative with the financing with Nemus.

See article for AXIM breakdown:
https://www.newcannabisventures.com/axim-biotechnology-extremely-overvalued/

Another head-scratcher of a day when you start to think the uptrend is in force....

Not that today's news was groundbreaking, but the consistent data and focus on science is assuring.

Its sort of mind-blowing the total lack of interest with the market cap so low.

VBIO is trading at 5x the market cap? I was certain it had started to come crashing down, but it has somehow stairstepped back up all of its losses. I can't find any information about timeline of when they would actually start clinical trials. Definitely not in 2017, and cant find any information about early 2018. Nor is there any data about drugs they are formulating, or animal-model results.

Anybody have any links to ANY of this information on VBIO that would be critical to a drug company? Or do drug companies not need this anymore, they just need to put money in PR campaigns.

Looking forward to 3Q. Painful seeing this get toyed with. $20 round financing was supposed to close by end of 2Q so hopefully July will bring us a catalyst of more data and then another catalyst with an NDA!

I thought the analysis on this board regarding Inmed & Nemus has been pretty accurate. I have to agree with Vinpat in regards to the fact that their biosynthesis is wildly inflated and may not be that beneficial as opposed to what other companies are doing.

Their entire claim behind their technology/software is speed, which is that their process allows them to identify cannabinoids best suited for certain diseases without doing heavy amount of trials and research. Theoretically, this would mean that they would be able to identify a variety of targets faster than any other company, or so they claim.

However, right now they have only two targets in their pipeline, meanwhile they've been at it with this system of biosynthesis for years.

See below for Seeking Alpha article from March 2015. They have essentially missed all expected timelines and are not much further along then they were over 2 years ago. Their pipeline has actually shrinked, and they haven't advanced on those targets.

https://seekingalpha.com/instablog/27523743-point-of-return/3789506-all-natural-the-opportunity-in-pharmaceutical-cannabinoid-medicine-with-inmed-pharmaceuticals-inc

If their science was that superb, you'd think they would have been further along or wouldve been able to secure more funding by now. The 5 million raise will keep them afloat for now but they are clearly very far behind in moving towards trials.

LOL

They didn't invest with insider information!??! Who gives out 20 million without 100% knowledge of whats going on behind the scenes at Nemus. NOBODY.

Your DD leads you to this board. Their DD leads them to write a 20 million check. If 1 drug gets approved for them down the road, they will blitz past a 1 billion market cap, so Vinpat's analysis is pretty accurate.

Couple things to note.

While normally r/s are related to poor management and scam companies, this situation wouldn't be a detriment to the company.

Crazy as it may be, I think the IP and science that Nemus is keeping underwraps could propel this to where they need to be to uplist without a R/s. It's got a ways to go, but the expeditied process of a 505(b)(2) for the CINV target will be the launchpad.

Murphy never gave dates of when they are looking to uplist, so it is likely that they are looking to do this once they are through the 505(b)(2) process, which will likely be 4Q, and possibly once they have began Glaucoma trials.